A modest Utah-based molecular diagnostics company became extremely important in the spring of 2020 as labs around the country rushed to process more COVID-19 tests than their supply chains and equipment could manage. Before the pandemic created a worldwide market for precisely what Co-Diagnostics, Inc. produced, the company was working in relative obscurity on proprietary PCR testing technology. The moment was reflected in the stock. As investors sought exposure to the COVID testing economy, shares that had traded in ranges that attracted little market attention saw a significant increase, and Co-Diagnostics briefly seemed to be in the perfect position. The company’s pre-pandemic fundamentals would never have predicted the market capitalization’s ascent. The numbers were exceptional for a while.
The stats as of right now are completely different. As of April 2026, Co-Diagnostics’ market capitalization ranges from $3.52 million to $10 million, depending on the day and the current share price, which is between $1.70 and $1.86 per share. The company is trading close to its 52-week lows, with NASDAQ compliance issues in the background. About $507,890 is the trailing twelve-month revenue. About $32.18 million is the trailing twelve-month net loss. With its present burn rate, the company’s approximately $11.44 million in cash on hand is not an endless runway. In public markets, the difference between the valuation during the pandemic and the current one is as striking as it gets.
| Category | Details |
|---|---|
| Company Name | Co-Diagnostics, Inc. |
| Ticker Symbol | CODX (NASDAQ) |
| Headquarters | Utah, United States |
| Focus | Molecular diagnostics (PCR testing, rapid tests, nucleic acid detection) |
| Market Cap (April 2026) | ~$3.52M – $10M |
| Stock Price (April 2026) | ~$1.70 – $1.86 per share |
| Annual Revenue (TTM) | ~$507,890 |
| Net Loss (TTM) | ~-$32.18 Million |
| Cash on Hand | ~$11.44 Million |
| Peak Period | 2020–2021 (COVID-19 PCR testing demand) |
| Current Risk | NASDAQ compliance issues — share price near 52-week lows |
| Reference Website |
This story’s form is not wholly unique; scores of businesses whose fortunes were boosted by COVID-era demand have gone through similar corrections when that demand faded. Manufacturers of vaccines, providers of personal protective equipment (PPE), telemedicine platforms, and diagnostic testing firms all profited from an emergency that eventually subsided or at least returned to a level where the emergency premium in their stock prices was no longer sustainable. The extent of the collapse, the speed at which it happened, and the difference between the revenue and loss rates make Co-Diagnostics’ particular situation worth looking at. Losing $32 million in a year while making $507,000 in revenue indicates a company that has not yet discovered a post-pandemic business model capable of funding its operations.
Cooperative primer technique for PCR testing, a proprietary method of nucleic acid detection, served as the foundation for Co-Diagnostics’ business. This technology was actually helpful and is still relevant today. Beyond COVID-19 testing, the field of molecular diagnostics include infectious disease detection, genetic marker analysis, and uses in non-healthcare businesses that the company has pursued through licensing agreements. The dilemma for the corporation is whether the post-pandemic version of the business can be constructed around those competencies at a scale and pace that the remaining cash supports. This question is made urgent by the stock price and compliance concerns.
A timeline strain that is independent of the operational problems is added by the NASDAQ compliance predicament. With CODX trading in the low single digits close to its 52-week lows, the firm is in the range where that compliance risk becomes serious. NASDAQ’s ongoing listing rules require companies to maintain minimum bid price thresholds—$1 per share sustained for a period of time. Reverse stock splits, which reduce the number of shares and mechanically boost the price per share without altering the company’s core worth, are frequently used by companies that fall below the minimum bid price level to make amends within 180 days. Depending on how the stock moves in the upcoming months, Co-Diagnostics may or may not need to carry out that kind of reorganization.
The amount that most directly affects the company’s immediate future is the cash on hand figure of $11.44 million. The burn rate is substantial in comparison to the available runway, with $32 million in net losses on $507,000 in sales over the previous year. As the business commercializes its technology in new diagnostic applications, the revenue trajectory might increase. It’s also feasible that the funding runs out more quickly than the company grows, necessitating further capital rounds in a market that is far less supportive of small-cap diagnostics firms than it was during the epidemic.
Looking at Co-Diagnostics’ financial history between 2021 and 2026, there’s a sense that the pandemic produced a version of the company’s story that was never going to be the permanent version—a brief elevation motivated by an emergency that ultimately passed, leaving the underlying company to be valued on its own terms once more. At the moment, those terms are rather challenging.
